open access

Vol 9, No 7 (2004)
Published online: 2004-01-01
Submitted: 2004-05-06
Get Citation

Dose-effect relationship in cardiovascular brachytherapy

Jerzy Pręgowski, Wojciech Bulski, łukasz Kalińczuk, Mariusz Kruk, Adam Witkowski
DOI: 10.1016/S1507-1367(04)71040-8
·
Rep Pract Oncol Radiother 2004;9(7):301-306.

open access

Vol 9, No 7 (2004)
Published online: 2004-01-01
Submitted: 2004-05-06

Abstract

Restenosis after the PTCA (percutaneus transluminal cardiovascular angioplasty) is the most common failure of the invasive treatment in cardiology. The PTCA re-treatment is likely to be followed by repeated restenosis. A well evidenced effective method of restenosis prevention is cardiovascular brachytherapy. A radioactive source, gamma or beta emitter, is introduced into the vessel after the PTCA. The target to be irradiated is the neointima, tissue responsible for the cell proliferation after the PTCA trauma. For dose distribution planning two methods may be used: the so-called “standard dosimetry” and “individual dosimetry”. There exists some controversy concerning dependence of the effectiveness of cardiovascular brachytherapy on the dose delivered and the aim of this paper is to discuss views concerning late effects of brachytherapy. Important role of the analysis of dose-volume histograms (DVH) in cardiovascular brachytherapy is stressed. Description of dose-dependent late adverse side-effects in brachytherapy of cardiovascular restenosis is also given.

Abstract

Restenosis after the PTCA (percutaneus transluminal cardiovascular angioplasty) is the most common failure of the invasive treatment in cardiology. The PTCA re-treatment is likely to be followed by repeated restenosis. A well evidenced effective method of restenosis prevention is cardiovascular brachytherapy. A radioactive source, gamma or beta emitter, is introduced into the vessel after the PTCA. The target to be irradiated is the neointima, tissue responsible for the cell proliferation after the PTCA trauma. For dose distribution planning two methods may be used: the so-called “standard dosimetry” and “individual dosimetry”. There exists some controversy concerning dependence of the effectiveness of cardiovascular brachytherapy on the dose delivered and the aim of this paper is to discuss views concerning late effects of brachytherapy. Important role of the analysis of dose-volume histograms (DVH) in cardiovascular brachytherapy is stressed. Description of dose-dependent late adverse side-effects in brachytherapy of cardiovascular restenosis is also given.

Get Citation

Keywords

restenoza; brachyterapia wewnątrzwieńcowa

About this article
Title

Dose-effect relationship in cardiovascular brachytherapy

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 9, No 7 (2004)

Pages

301-306

Published online

2004-01-01

DOI

10.1016/S1507-1367(04)71040-8

Bibliographic record

Rep Pract Oncol Radiother 2004;9(7):301-306.

Keywords

restenoza
brachyterapia wewnątrzwieńcowa

Authors

Jerzy Pręgowski
Wojciech Bulski
łukasz Kalińczuk
Mariusz Kruk
Adam Witkowski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl